Paolo Alfieri

Dr. Paolo Alfieri

Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2014 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
Paolo AlfieriPaolo Alfieri
Paolo Alfieri
GPGiorgia Piccini
Giorgia Piccini
CCCristina Caciolo
Cristina Caciolo
FPFrancesca Perrino
Francesca Perrino
MGMaria Luigia Gambardella
Maria Luigia Gambardella
SVStefano Vicari
Stefano Vicari

1 January 2018 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
FPFrancesca Perrino
Francesca Perrino
SLSerena Licchelli
Serena Licchelli
GSGiulia Serra
Giulia Serra
GPGiorgia Piccini
Giorgia Piccini
CCCristina Caciolo
Cristina Caciolo
SVStefano Vicari
Stefano Vicari

16 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SVStefano Vicari
Stefano Vicari
GPGiorgia Piccini
Giorgia Piccini
EMEugenio Mercuri
Eugenio Mercuri
Roberta BattiniRoberta Battini
Roberta Battini
DCDaniela Chieffo
Daniela Chieffo
Paolo AlfieriPaolo Alfieri
Paolo Alfieri
This study aimed at comparing implicit sequence learning in individuals affected by Duchenne Muscular Dystrophy without intellectual disability and age-matched typically developing children. A modified version of the Serial Reaction Time task was administered to 32 Duchenne children and 37 controls of comparable chronological age. The Duchenne group showed a reduced rate of implicit learning even if in the absence of global intellectual disability. This finding provides further evidence of the involvement of specific aspects of cognitive function in Duchenne muscular dystrophy and on its possible neurobiological substrate.

Verified
Journal Article
Open access
PDF file
ASAntonella Sferra
Antonella Sferra
SPStefania Petrini
Stefania Petrini
EBEmanuele Bellacchio
Emanuele Bellacchio
Francesco NicitaFrancesco Nicita
Francesco Nicita
FSFrancesco Scibelli
Francesco Scibelli
GZGinevra Zanni
Ginevra Zanni
Tubulinopathies are rare neurological disorders caused by alterations in tubulin structure and function, giving rise to a wide range of brain abnormalities involving neuronal proliferation, migration, differentiation and axon guidance. TUBB is one of the ten β-tubulin encoding genes present in the human genome and is broadly expressed in the developing central nervous system and the skin. Mutations in TUBB are responsible for two distinct pathological conditions: the first is characterized by microcephaly and complex structural brain malformations and the second, also known as “circumferential skin creases Kunze type” (CSC-KT), is associated to neurological features, excess skin folding and growth retardation. We used a combination of immunocytochemical and cellular approaches to explore, on patients’ derived fibroblasts, the functional consequences of two TUBB variants: the novel mutation (p.N52S), associated with basal ganglia and cerebellar dysgenesis, and the previously reported variant (p.M73T), linked to microcephaly, corpus callosum agenesis and CSC-KT skin phenotype. Our results demonstrate that these variants impair microtubule (MT) function and dynamics. Most importantly, our studies show an altered epidermal growth factor (EGF) and transferrin (Tf) intracellular vesicle trafficking in both patients’ fibroblasts, suggesting a specific role of TUBB in MT-dependent vesicular transport.

13 March 2018 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
CCCristina Caciolo
Cristina Caciolo
Paolo AlfieriPaolo Alfieri
Paolo Alfieri
GPGiorgia Piccini
Giorgia Piccini
MDMaria Cristina Digilio
Maria Cristina Digilio
FLFrancesca Romana Lepri
Francesca Romana Lepri
SVStefano Vicari
Stefano Vicari
Background: Kabuki syndrome (KS) is a disorder characterized by multiple congenital anomalies affecting development and function of multiple systems. Over the years, researchers have attempted to characterize the neurobehavioral phenotype of KS in cohorts of patients enrolled on the basis of clinical assessment. The availability of molecular testing now allows for recruitment of patients with confirmed KS due to KMT2D and KDM6A.Methods: The aims of the present study were to investigate the neuropsychological and behavioral profiles of individuals with molecularly confirmed diagnosis of KS, and determine the extent of heterogeneity occurring in these profiles between individuals with clinical diagnosis of KS with and without mutations in KMT2D. We also described performance of our cohort in any neuropsychological domain investigated.Results: We documented a marked variation in the neuropsychological profile of subjects with clinical diagnosis of KS, even though a relatively homogeneous impairment in linguistic domains and motor skills was observed. No significant difference occurred between mutation‐positive and mutation‐negative groups. Phonological disorders and oromotor dysfunctions were also found, and adaptive functioning was characterized by low performance in daily living and in motor domain.Conclusion: The present study allowed identification of a distinctive neurobehavioral profile in a cohort of individuals affected by KS with or without molecularly confirmed diagnosis. These findings are expected to help clinicians define more accurately targeted protocols for individualized intervention.

Verified
Journal Article
Open access
PDF file
FLFrancesca Romana Lepri
Francesca Romana Lepri
DCDario Cocciadiferro
Dario Cocciadiferro
BABartolomeo Augello
Bartolomeo Augello
Paolo AlfieriPaolo Alfieri
Paolo Alfieri
VPValentina Pes
Valentina Pes
Giuseppe MerlaGiuseppe Merla
Giuseppe Merla
Kabuki syndrome (KS) is a rare disorder characterized by multiple congenital anomalies and variable intellectual disability caused by mutations in KMT2D/MLL2 and KDM6A/UTX, two interacting chromatin modifier responsible respectively for 56–75% and 5–8% of the cases. To date, three KS patients with mosaic KMT2D deletions in blood lymphocytes have been described. We report on three additional subjects displaying KMT2D gene mosaics including one in which a single nucleotide change results in a new frameshift mutation (p.L1199HfsX7), and two with already-known nonsense mutations (p.R4484X and p.R5021X). Consistent with previously published cases, mosaic KMT2D mutations may result in mild KS facial dysmorphisms and clinical and neurobehavioral features, suggesting that these characteristics could represent the handles for genetic testing of individuals with slight KS-like traits.